{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:39Z","timestamp":1791593859757,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical hemolytic uremic Syndrome (aHUS), a form of thrombotic microangiopathy (TMA), had a poor prognosis until the development of complement C5-inhibiting monoclonal antibodies, eculizumab and ravulizumab. While ravulizumab has shown effectiveness in treating postpartum TMA, data about its use during pregnancy remains lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 32-year-old woman with a history of aHUS was initially diagnosed in 2018 at the age of 27 after presenting with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) requiring hemodialysis and plasma exchange. Kidney biopsy showed evidence of TMA, and genetic testing identified a pathogenic CD46 (MCP) variant, confirming complement-mediated aHUS. She achieved complete hematologic and renal recovery with eculizumab therapy and remained dialysis-independent thereafter. Eculizumab was continued until 2021, with brief interruptions during the COVID-19 pandemic, due to intermittent drug shortages. Treatment was discontinued, and the patient remained clinically stable under close monitoring. In 2022, during routine follow-up, she was found to be pregnant without complications. The pregnancy was unplanned; however, she was closely monitored throughout early gestation with regular assessments of renal function, hematologic parameters, blood pressure, proteinuria, and complement activity. Prophylactic complement inhibition was not initiated during early pregnancy because eculizumab was unavailable, and she remained in remission during the first trimester. At 25\u2009weeks\u2019 gestation, she developed a relapse of aHUS characterized by vomiting, diarrhea, anemia, thrombocytopenia, hypertension, and AKI. Stool testing for Shiga toxin\u2013producing Escherichia coli was negative. Eculizumab was unavailable; thus, after informed consent, ravulizumab was initiated based on her body weight as per the manufacturer\u2019s label: a loading dose of 2,700\u2009mg on Day 1 and a maintenance dose of 3,300\u2009mg on Day 14, and subsequently 3300\u2009mg every eight weeks. The patient achieved rapid hematologic and renal recovery and had a spontaneous full-term vaginal delivery without maternal or neonatal complications. Both mother and child remained well after about four years of follow-up on ravulizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case report highlights the potential role of ravulizumab in managing aHUS during pregnancy. Given the limited safety data, further studies are needed to guide its use in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04950-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:27:00Z","timestamp":1776256020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report on the effective and safe use of ravulizumab in atypical hemolytic uremic syndrome during pregnancy"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3860-5074","authenticated-orcid":false,"given":"Abdulaziz","family":"Alkhaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoun","family":"Elawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Al Dalbhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"Alquraini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanoud","family":"Alshannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4950_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"4950_CR2","first-page":"1073","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073\u201386.","journal-title":"Lancet"},{"key":"4950_CR3","doi-asserted-by":"publisher","unstructured":"Loirat C, Fr\u00e9meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011. https:\/\/doi.org\/10.1186\/1750-1172-6-60.","DOI":"10.1186\/1750-1172-6-60"},{"key":"4950_CR4","doi-asserted-by":"publisher","unstructured":"Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004. https:\/\/doi.org\/10.1053\/j.ajkd.2004.02.010. PubMed PMID: 15168377.","DOI":"10.1053\/j.ajkd.2004.02.010"},{"key":"4950_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol"},{"key":"4950_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. NEJM Evid. 2013;368:2169\u201381.","journal-title":"NEJM Evid"},{"key":"4950_CR7","doi-asserted-by":"publisher","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010. https:\/\/doi.org\/10.2215\/CJN.02210310. PubMed PMID: 20595690.","DOI":"10.2215\/CJN.02210310"},{"key":"4950_CR8","doi-asserted-by":"publisher","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016. https:\/\/doi.org\/10.1007\/s00467-015-3076-8.","DOI":"10.1007\/s00467-015-3076-8"},{"key":"4950_CR9","unstructured":"Alexion Pharmaceuticals. Soliris\u00ae (eculizumab) prescribing information. 2024. Available from: https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/soliris_uspi.pdf. Accessed 23 Apr 2025."},{"key":"4950_CR10","doi-asserted-by":"publisher","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035. PubMed PMID: 32299680.","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"4950_CR11","doi-asserted-by":"publisher","unstructured":"G\u00e4ckler A, Sch\u00f6nermarck U, Dobronravov V, La Manna G, Denker A, Liu P, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021. https:\/\/doi.org\/10.1186\/s12882-020-02190-0.","DOI":"10.1186\/s12882-020-02190-0"},{"key":"4950_CR12","unstructured":"Alexion Pharmaceuticals Inc. Ravulizumab prescribing information. 2022."},{"key":"4950_CR13","doi-asserted-by":"publisher","unstructured":"Tzur A, Czuzoj-Shulman N, Abenhaim HA. Atypical hemolytic uremic syndrome and pregnancy outcomes: a cohort study. Am J Obstet Gynecol. 2023;228:S437\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2022.11.758.","DOI":"10.1016\/j.ajog.2022.11.758"},{"key":"4950_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","volume":"22","author":"A G\u00e4ckler","year":"2021","unstructured":"G\u00e4ckler A, Sch\u00f6nermarck U, Dobronravov V, La Manna G, Denker A, Liu P, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021;22:5.","journal-title":"BMC Nephrol"},{"key":"4950_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2021","unstructured":"Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele \u00c5, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin Nephrol. 2021;97:261.","journal-title":"Clin Nephrol"},{"key":"4950_CR16","doi-asserted-by":"publisher","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2021. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046.","DOI":"10.1016\/j.kint.2020.10.046"},{"key":"4950_CR17","doi-asserted-by":"publisher","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020. https:\/\/doi.org\/10.1016\/j.kint.2020.01.035.","DOI":"10.1016\/j.kint.2020.01.035"},{"key":"4950_CR18","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137:2438\u201349.","journal-title":"Blood"},{"key":"4950_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fr\u00e9meaux-Bacchi V. French Study Group for aHUS\/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643\u201357.","journal-title":"Nat Rev Nephrol"},{"key":"4950_CR20","doi-asserted-by":"publisher","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015. https:\/\/doi.org\/10.1038\/ki.2014.423.","DOI":"10.1038\/ki.2014.423"},{"key":"4950_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Roumenina L, Provot F, Sall\u00e9e M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21:859\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"4950_CR22","doi-asserted-by":"publisher","unstructured":"Rondeau E, Ardissino G, Caby-Tosi MP, Al-Dakkak I, Fakhouri F, Miller B, et al. Pregnancy in women with atypical hemolytic uremic syndrome. Nephron. 2022. https:\/\/doi.org\/10.1159\/000518171 PubMed PMID: 34515154.","DOI":"10.1159\/000518171"},{"key":"4950_CR23","doi-asserted-by":"crossref","unstructured":"Jacob A, Mahmoud A, Eldweik L, Mubashir A. Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report. BMJ Neurol Open. 2025;7:e001286.","DOI":"10.1136\/bmjno-2025-001286"},{"key":"4950_CR24","doi-asserted-by":"crossref","unstructured":"H\u00f6chsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, et al. Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy. Blood Adv. 2026.","DOI":"10.1182\/bloodadvances.2025019253"},{"key":"4950_CR25","doi-asserted-by":"publisher","unstructured":"Menne J. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? Kidney Int. 2020. https:\/\/doi.org\/10.1016\/j.kint.2020.03.011. PubMed PMID: 32444092.","DOI":"10.1016\/j.kint.2020.03.011"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04950-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04950-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04950-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:06:17Z","timestamp":1781647577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04950-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4950"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04950-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report study was conducted in accordance with the principles of the Declaration of Helsinki. It was reviewed and approved by the Institutional Review Board (IRB) of Prince Sultan Military Medical City, Riyadh, Saudi Arabia (IRB approval number: 1439).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the clinical details in this case report was obtained from the patient; no identifying images or personal identifiers are included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}